Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.

about

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.

Item

http://www.wikidata.org/entity/Q38958933

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cost-effectiveness of dipeptid ...... ic kidney disease in Thailand.

@en

type

Item

label

Cost-effectiveness of dipeptid ...... ic kidney disease in Thailand.

@en

prefLabel

Cost-effectiveness of dipeptid ...... ic kidney disease in Thailand.

@en

P1476

Cost-effectiveness of dipeptid ...... ic kidney disease in Thailand.

@en

P2093

Nathorn Chaiyakunapruk

http://www.w3.org/2001/XMLSchema#string

Piyameth Dilokthornsakul

http://www.w3.org/2001/XMLSchema#string

Unchalee Permsuwan

http://www.w3.org/2001/XMLSchema#string

P2860

Use of metformin in the setting of mild-to-moderate renal insufficiency

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison

Thiazolidinediones.

Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Diabetes management in Thailand: a literature review of the burden, costs, and outcomes.

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina

P304

171-181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13696998.2016.1238386

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kednapa Thavorn

Surasak Saokaew

P577

2016-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27645706

http://www.w3.org/2001/XMLSchema#string

P921

An Téalainn